Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV003235115 | SCV003934949 | likely benign | Rett syndrome | 2023-06-15 | reviewed by expert panel | curation | The allele frequency of the c.714G>A p.Gly238= variant in MECP2 is 0.008% in the African/African American sub population in gnomAD, which is high enough to meet the BS1 criteria based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1). The silent p.Gly238= variant is not predicted to affect splicing using multiple computational tools and does not affect a highly conserved nucleotide (BP4, BP7). In summary, the c.714G>A p.Gly238= variant in MECP2 is classified as Likely Benign based on the ACMG/AMP criteria (BS1, BP4, BP7). |
Genetic Services Laboratory, |
RCV000192514 | SCV000247989 | uncertain significance | not specified | 2013-02-08 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000192514 | SCV000513563 | benign | not specified | 2015-03-19 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV001515210 | SCV001723230 | benign | Severe neonatal-onset encephalopathy with microcephaly | 2024-01-14 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004734849 | SCV005346282 | likely benign | MECP2-related disorder | 2022-02-08 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |